Genetics of Bariatric Surgery Outcomes

Endocrinology and Metabolism Clinics of North America

Volumn 45, Issue 3, 2016, Pages 623-632

  Noel, Olivier F ^a,b,c   Still, Christopher D ^d   Gerhard, Glenn S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c DNAsimple   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

Author keywords

Bariatric surgery; Genetics; NAFLD; Type 2 diabetes mellitus; Weight loss

Indexed keywords

BILE ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; ESTROGEN RECEPTOR ALPHA; FARNESOID X RECEPTOR; INTERLEUKIN 27; MELANIN CONCENTRATING HORMONE RECEPTOR 1; SIRTUIN 2; SOMATOMEDIN C RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

APOBR GENE; APOC3 GENE; AS3MT GENE; BARIATRIC SURGERY; BDNF GENE; DISEASE ASSOCIATION; ESTROGEN RECEPTOR 1 GENE; FXR GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GTF3A GENE; HMGCR GENE; HUMAN; IGF1R GENE; IL27 GENE; LIPID ANALYSIS; LPL GENE; MAP2K5 GENE; MAP3K12 GENE; MAP3K14 GENE; MAP3K15 GENE; MCHR1 GENE; METTL13 GENE; METTL21C GENE; METTL6 GENE; METTL7A GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NT5C2 GENE; OLFM4 GENE; OUTCOME ASSESSMENT; PEPD GENE; PINX1 GENE; PLA2G6 GENE; PRIORITY JOURNAL; REVIEW; RPS3A GENE; SEC16B GENE; SH2B1 GENE; SIRT2 GENE; SULT1A2 GENE; TMEM184B GENE; WEIGHT REDUCTION; BODY WEIGHT LOSS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; TREATMENT OUTCOME;

BARIATRIC SURGERY; BILE ACIDS AND SALTS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84994464060     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2016.04.011     Document Type: Review

References (52)

1. 1 Courcoulas, A.P., Yanovski, S.Z., Bonds, D., et al. Long-term outcomes of bariatric surgery: a National Institutes of Health symposium. JAMA Surg 149:12 (2014), 1323–1329.
2. 2 Still, C.D., Wood, G.C., Chu, X., et al. Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 22:3 (2014), 888–894.
3. 3 Allen, R.E., Hughes, T.D., Ng, J.L., et al. Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetes. Theor Biol Med Model, 10, 2013, 45.
4. 4 Madsbad, S., Dirksen, C., Holst, J.J., Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2:2 (2014), 152–164.
5. 5 Nguyen, K.T., Korner, J., The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery. Curr Diab Rep, 14(5), 2014, 481.
6. 6 Prawitt, J., Caron, S., Staels, B., Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 11:3 (2011), 160–166.
7. 7 Hoeke, M.O., Heegsma, J., Hoekstra, M., et al. Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS One, 9(2), 2014, e88011.
8. 8 Ryan, K.K., Tremaroli, V., Clemmensen, C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:7499 (2014), 183–188.
9. 9 Eldar, S., Heneghan, H.M., Brethauer, S.A., et al. Bariatric surgery for treatment of obesity. Int J Obes (Lond) 35:Suppl 3 (2011), S16–S21.
10. 10 Hatoum, I.J., Greenawalt, D.M., Cotsapas, C., et al. Heritability of the weight loss response to gastric bypass surgery. J Clin Endocrinol Metab 96:10 (2011), E1630–E1633.
11. 11 Elkhenini, H.F., New, J.P., Syed, A.A., Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation. Clin Obes 4:2 (2014), 121–124.
12. 12 Matzko, M.E., Argyropoulos, G., Wood, G.C., et al. Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery. Obes Surg 22:5 (2012), 783–790.
13. 13 de Luis, D.A., Aller, R., Conde, R., et al. Effects of RS9939609 gene variant in FTO gene on weight loss and cardiovascular risk factors after biliopancreatic diversion surgery. J Gastrointest Surg 16:6 (2012), 1194–1198.
14. 14 Liou, T.H., Chen, H.H., Wang, W., et al. ESR1, FTO, and UCP2 genes interact with bariatric surgery affecting weight loss and glycemic control in severely obese patients. Obes Surg 21:11 (2011), 1758–1765.
15. 15 Still, C.D., Wood, G.C., Chu, X., et al. High allelic burden of four obesity SNPs is associated with poorer weight loss outcomes following gastric bypass surgery. Obesity (Silver Spring) 19:8 (2011), 1676–1683.
16. 16 Locke, A.E., Kahali, B., Berndt, S.I., et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518:7538 (2015), 197–206.
17. 17 Shungin, D., Winkler, T.W., Croteau-Chonka, D.C., et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518:7538 (2015), 187–196.
18. 18 Hatoum, I.J., Greenawalt, D.M., Cotsapas, C., et al. Weight loss after gastric bypass is associated with a variant at 15q26.1. Am J Hum Genet 92:5 (2013), 827–834.
19. 19 Kuipers, F., Bloks, V.W., Groen, A.K., Beyond intestinal soap–bile acids in metabolic control. Nat Rev Endocrinol 10:8 (2014), 488–498.
20. 20 van der Klaauw, A.A., Farooqi, I.S., The hunger genes: pathways to obesity. Cell 161:1 (2015), 119–132.
21. 21 Duckworth, P.F., Vlahcevic, Z.R., Studer, E.J., et al. Effect of hydrophobic bile acids on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and mRNA levels in the rat. J Biol Chem 266:15 (1991), 9413–9418.
22. 22 Vivacqua, G., Renzi, A., Carpino, G., et al. Expression of brain derivated neurotrophic factor and of its receptors: TrKB and p75NT in normal and bile duct ligated rat liver. Ital J Anat Embryol 119:2 (2014), 111–129.
23. 23 Verlaet, M., Adamantidis, A., Coumans, B., et al. Human immune cells express ppMCH mRNA and functional MCHR1 receptor. FEBS Lett 527:1–3 (2002), 205–210.
24. 24 Krishnan, J., Danzer, C., Simka, T., et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev 26:3 (2012), 259–270.
25. 25 Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:17 (2012), 1577–1585.
26. 26 Buchwald, H., Estok, R., Fahrbach, K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:3 (2009), 248–256.e5.
27. 27 Frayn, K.N., Humphreys, S.M., Metabolic characteristics of human subcutaneous abdominal adipose tissue after overnight fast. Am J Physiol Endocrinol Metab 302:4 (2012), E468–E475.
28. 28 Fisette, A., Poursharifi, P., Oikonomopoulou, K., et al. Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice. Mediators Inflamm, 2013, 2013, 713284.
29. 29 Germinario, R., Sniderman, A.D., Manuel, S., et al. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42:5 (1993), 574–580.
30. 30 Cariou, B., van Harmelen, K., Duran-Sandoval, D., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281:16 (2006), 11039–11049.
31. 31 Lange, L.A., Willer, C.J., Rich, S.S., Recent developments in genome and exome-wide analyses of plasma lipids. Curr Opin Lipidol 26:2 (2015), 96–102.
32. 32 Parihar, A., Wood, G.C., Chu, X., et al. Extension of GWAS results for lipid-related phenotypes to extreme obesity using electronic health record (EHR) data and the Metabochip. Front Genet, 5, 2014, 222.
33. 33 Lim, S., Eckel, R.H., Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord 15:4 (2014), 329–341.
34. 34 Del Ben, M., Polimeni, L., Baratta, F., et al. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 20:26 (2014), 8341–8350.
35. 35 Hafeez, S., Ahmed, M.H., Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. J Obes, 2013, 2013, 839275.
36. 36 Mattar, S.G., Velcu, L.M., Rabinovitz, M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242:4 (2005), 610–617 [discussion: 618–20].
37. 37 Mottin, C.C., Moretto, M., Padoin, A.V., et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 15:6 (2005), 788–793.
38. 38 Klein, S., Mittendorfer, B., Eagon, J.C., et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130:6 (2006), 1564–1572.
39. 39 Barker, K.B., Palekar, N.A., Bowers, S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101:2 (2006), 368–373.
40. 40 Csendes, A., Smok, G., Burgos, A.M., Histological findings in the liver before and after gastric bypass. Obes Surg 16:5 (2006), 607–611.
41. 41 de Almeida, S.R., Rocha, P.R., Sanches, M.D., et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 16:3 (2006), 270–278.
42. 42 Furuya, C.K. Jr., de Oliveira, C.P., de Mello, E.S., et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22:4 (2007), 510–514.
43. 43 Liu, X., Lazenby, A.J., Clements, R.H., et al. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 17:4 (2007), 486–492.
44. 44 Weiner, R.A., Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 28:1 (2010), 274–279.
45. 45 Moretto, M., Kupski, C., da Silva, V.D., et al. Effect of bariatric surgery on liver fibrosis. Obes Surg 22:7 (2012), 1044–1049.
46. 46 Ranlov, I., Hardt, F., Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 47:4 (1990), 208–214.
47. 47 Stratopoulos, C., Papakonstantinou, A., Terzis, I., et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 15:8 (2005), 1154–1160.
48. 48 Dixon, J.B., Bhathal, P.S., Hughes, N.R., et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39:6 (2004), 1647–1654.
49. 49 Dixon, J.B., Bhathal, P.S., O'Brien, P.E., Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16:10 (2006), 1278–1286.
50. 50 Mathurin, P., Hollebecque, A., Arnalsteen, L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:2 (2009), 532–540.
51. 51 Kral, J.G., Thung, S.N., Biron, S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135:1 (2004), 48–58.
52. 52 DiStefano, J.K., Kingsley, C., Craig Wood, G., et al. Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetol 52:2 (2015), 373–382.